期刊文献+

^18F-FLTPET/CT与^18F—FDGPET/CT在鼻咽癌诊断和分期中的应用比较 被引量:5

A comparative study of ^18F-FLT PET/CT and ^18F-FDG PET/CT in patients with nasopharyngeal carcinoma
原文传递
导出
摘要 目的通过与^18F-FDGPET/CT显像对比,探讨^18F-FLTPET/CT检测鼻咽癌原发灶和颈部淋巴结转移灶的可行性。方法12例初治且经病理确诊的鼻咽癌患者(年龄22-62岁)自愿进入该前瞻.陛临床研究。每位患者先行^18F-FDGPET/CT检查,次日行^18F-FLTPET/CT检查。至少有2位核医学科和放射科医师阅片,比较^F-8FDGPET/CT和^18F-FLTPET/CT图像,采用ROI技术计算鼻咽肿瘤、颈部淋巴结转移灶、正常组织对^18F-FDG、^18F-FLT的SUVmax、SUVmean。和MTV。采用非参数Wilcoxon秩和检验比较组问摄取和MTV差异。结果12例鼻咽癌患者病灶均明显摄取^18F-FLToTMF-FuPET/CT和^18F-FDGPET/CT均可准确诊断该组病例,二者对原发灶和淋巴结转移灶的检测结果无明显差别。鼻咽癌病灶的^18F-FDG和^18F-FLT SUVmax分别为10.7±5.8和6.0±2.4,SUVmean。分别为5.8±3.0和3.6±1.5;SUVmax和SUVmean。组间差异均有统计学意义(Z=-2.589和-2.353,P均〈0.05),而MTV在^18F-FDG和^18F-FLTPET/CT2种显像方法之间的差异无统计学意义(15.9±9.2和18.1±11.1;Z=-0.786,P〉0.05)。6例有颈部淋巴结转移灶患者的SUVmax、SUVmean和MTV在2种显像方法间差异均无统计学意义(8.5±6.2比6.4±2.5、5.3±4.2比3.8±1.4、6.5±4.8比6.0±4.4;Z=-0.734、-0.734和-0.674,P均〉0.05)。^18F-FLT在颞叶摄取(SUVmax0.7±0.3)明显低于^18F-FDG(SUVmax8.3±2.7;Z=-3.062,P〈0.01),其对于原发灶颅内浸润显示较^18F-FDG更清晰。结论”F-FLT PET/CT在鼻咽癌原发灶和淋巴结转移灶的诊断效能与^18F-FDGPET/CT相当,对于显示原发灶的颅底附近侵犯更有利,其临床应用值得进-步研究。 Objective To investigate the value of ^18 F-FLT compared to ^18 F-FDG in PET/CT diag- nosis of nasopharyngeal carcinoma (NPC). Methods Twelve newly biopsy-proven NPC patients (age range: 22 -62 years) were prospectively enrolled into this study after obtaining patient consent. They un- derwent ^18F-FDG FET/CT first, followed by ^18F-FLT PET/CT on the consecutive day before treatment. ROIs were drawn on the primary tumor, involved lymph nodes and normal tissues. Wilcoxon rank sum test was used to compare the uptake differences between ^18F-FLT and ^18F-FDG for both the primary tumor and metastatic lymph nodes. Results All 12 patients showed increased uptake of ^18F-FLT by the primary tumor and metastatic lymph nodes, which were consistent with the findings by ^18F-FDG PET/CT. The SUVmax and SUV of ISF-FLT in the primary NPC (SUVmax 6. 0 ±2. 4, SUV 3.6 ± 1.5) were lower than those of ^18 F-FDG ( SUVmax 10.7 ± 5.8, SUVmcan 5.8 ± 3.0 ;Z = - 2. 589 and - 2. 353, both P 〈 0.05). However,the MTV on ^18F-FDG and ^18F-FLT PET/CT showed no significant difference (15.9 ±9.2 vs 18.1 ±11.1, Z= -0.786, P 〉 0.05). The SUV SUV and MTV of the metastatic cervical lymph nodes in 6 patients showed no significant difference between the 2 tracers (8.5 ± 6.2 vs 6.4 ± 2.5, 5.3 ±4.2 vs 3.8 ± 1.4, 6.5 ± 4.8 vs 6.0 ± 4.4 ; Z = - 0.734, - 0.734, - 0.674, respectively, all P 〉 0.05). The ^18F-FLT up- take in the normal temporal lobe (SUVmax 0. 7 ± 0. 3 ) was significantly lower than that of ^18F-FDG( SUVmax 8. 3 ±2. 7, Z = -3. 062, P 〈 0. 01 ). The skull base involvement by NPC could be better delineated on ^18F-FLT PET/CT. Conclusions ^18F-FLT PET/CT has comparable diagnostic efficacy for primary NPC and metastatic cervical lymph nodes to ^18 F-FDG PET/CT. It might he better than ^18F-FDG for the evaluation of skull base involvement in NPC patients.
出处 《中华核医学与分子影像杂志》 CSCD 北大核心 2012年第5期349-352,共4页 Chinese Journal of Nuclear Medicine and Molecular Imaging
基金 国家自然科学基金(81101066) 福建省科技计划(200839-11) 福建省卫生厅青年科研课题资助计划(2008-1-51) 厦门市科技计划(3502720077053)
关键词 鼻咽肿瘤 体层摄影术 发射型计算机 X线计算机 胸苷 脱氧葡萄糖 Nasopharyngeal neoplasms Tomography, emission-computed Tomography, X-raycomputed Thymidine Deoxyglueose
  • 相关文献

参考文献19

  • 1Haubner R. PET radiopharmaceuticals in radiation treatment plan- ning-synthesis and biological characteristics. Radiother Oncol, 2010, 96: 280-287.
  • 2Salskov A, Tammisetti VS, Grierson J, et al. FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[^18F] fluorothymidine. Semin Nucl Med, 2007, 37 : 429-439.
  • 3Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3' deoxy- 3'- [ ^18 F ] fluorothymidine ( [ ^18 F ] FLT ) as a proliferation imaging trac- er in humans : correlation of [ ^18F ] FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in hu- man lung tumors. Clin Cancer Res, 2002, 8: 3315-3323.
  • 4Smyezek-Gargya B, Fersis N, Dittmann H, et al. PET with [ ^18F] fluorothymidine for imaging of primary breast cancer : a pilot study. Eur J Nucl Med Mol Imaging, 2004, 31 : 720-724.
  • 5Yamamoto Y, Nishiyama Y, Ishikawa S, et al. Correlation of ^18F- FLT and ^18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging, 2007, 34: 1610-1616.
  • 6Yang W, Zhang Y, Fu Z, et al. Imaging of proliferation with ^18F- FLT PET/CT versus ^18F-FDG PET/CT in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging, 2010, 37: 1291-1299.
  • 7Han D, Yu J, Yu Y, et al. Comparison of ^18 F-fluorothymidine and ^18F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus. Int J Radiat Oncol Biol Phys, 2010, 76: 1235-1241.
  • 8van Westreenen HL, Cobben DC, Jager PL, et al. Comparison of ^18F-FLT PET and ^18F-FDG PET in esophageal cancer. J Nucl Med, 2005, 46: 400-404.
  • 9Burri R J, Rangaswamy B, Kostakoglu L, et al. Correlation of posi- tron emission tomography standard uptake value and pathologic specimen size in cancer of the head and neck. Int J Radiat Oncol Biol Phys, 2008, 71: 682-688.
  • 10Shields AF, Lim K, Grierson J, et al. Utilization of labeled thymi- dine in DNA synthesis: studies for PET. J Nucl Med, 1990, 31 : 337 -342.

二级参考文献11

  • 1谭业颖,田嘉禾,张锦明,姚树林,崔红英.^(18)F-FLT PET显像诊断肺单发结节及评价细胞增殖的价值[J].中华核医学杂志,2007,27(2):65-67. 被引量:20
  • 2Schiepers C, Dahlbom M, Chen W, et al. Kinetics of 3'-deoxy- 3'-^18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med, 2010, 51: 720-727.
  • 3Yue J, Chen L, Cabrera AR, et al. Measuring tumor cell prolifera- tion with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study. J Nucl Med, 2010, 51: 528 -534.
  • 4Yamamoto Y, Nishiyama Y, Kimura N, et al.Comparison of 18F- FLT PET and 18F-FDG PET for preoperative staging in non-small cell lung cancer. Eur J Nucl Med Mol Imaging, 2008, 35: 236- 245.
  • 5Herrmann K, Wieder HA, Buck AK, et al. Early response assess- ment using 3'-deoxy-3'-[ 18 F ] fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res, 2007, 13 : 3552-3558.
  • 6Wang H, Zhang J, Tian J, et al. Using dual-tracer PET to predict the biologic behavior of human colorectal cancer. J Nucl Med, 2009, 50: 1857-1864.
  • 7Ribas A, Benz MR, Allen-Auerbach MS, et al. Imaging of CTLA4 blockade-induced cell replication with ^18F-FLT PET/CT in patients with advanced melanoma treated with tremelimumab. J Nucl Med, 2010, 51 : 340-346.
  • 8Caroli P, Nanni C, Rubello D, et al. Non-FDG PET in the practice of oncology. Indian J Cancer, 2010, 47 : 120-125.
  • 9Brepoels L, Stroobants S, Verhoef G, et al. ^18F-FDG and ^18F-FLT uptake early after cyclophosphamide and roTOR inhibition in an experimental lymphoma model. J Nucl Med, 2009, 50 : 1102-1109.
  • 10马黎明,田嘉禾,杨小丰,于丽娟,陈萍,辛军,冯蕙茹,吴文凯,赵周社,李宏利,王爽.^18F-FDG和^18F-FLTPET/CT诊断肺结节影响因素的多中心临床研究[J].中国医学影像学杂志,2009,17(1):19-21. 被引量:13

共引文献5

同被引文献69

引证文献5

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部